FGFR2 and infantile convulsions and choreoathetosis: Targeted inhibition (using pemigatinib) in previously treated iCCA patients with FGFR2 gene alteration (fusions/rearrangements), showed objective response in 35.5% of patients compared to patients with other FGFR alterations or FGFR negative controls.